Watch our EBAC accredited video series "Transforming SCLC care" as @sands_jacob, @lungoncdoc, Stephanie McDonald, and @peters_solange discuss the management of ES-SCLC. Earn up to 20 minutes of CME across all three episodes
ow.ly/1pbo5105MGZ

#LungCancer #Oncology #MedEd

📰 It’s News-day Tuesday! A new blood test shows promise for accurately staging chronic liver disease using a routine blood sample. Plus, late-stage trial data show improvements in a key liver enzyme for people with primary biliary cholangitis
ow.ly/qP3j5105tBj

💛 This #BladderHealthMonth, explore the latest in #BladderCancer care. Access expert resources on diagnosis, management and emerging insights across #NMIBC and advanced disease, including our podcast hosted by @UroDocAsh
ow.ly/9oQw5104Y7h

🫁 Catch up on the latest lung cancer highlights from #ESMO26.

Explore key congress updates, expert insights and developments shaping the evolving treatment landscape of small-cell lung cancer (SCLC) and non–small-cell lung cancer (NSCLC) care

ow.ly/PO7A51040hy

🫁 November is Lung Cancer Awareness Month.

Keep up with the evolving treatment landscape with our Lung Cancer Nexus, and follow our socials for key resources throughout the month, including highlights from this year's WCLC, ASCO and ESMO congresses

ow.ly/WGXB5103ZYP

📰 It’s News-day Tuesday! New research highlights rising colorectal cancer rates across US adults and potential biological differences in younger patients. Plus, a targeted therapy combination shows promising survival outcomes in advanced kidney cancer
ow.ly/TSFZ5103kHY

Press play on the latest medical updates with Medthority’s YouTube channel. Explore expert interviews, podcasts, and congress highlights covering the topics that matter in clinical practice
youtube.com/@Medthority

Earn up to 70 minutes EBAC® CME credit and watch Benedikt Schoser, Derralynn Hughes, Christoph Wanner, and Karim Wahbi discuss Fabry management from childhood through to older adulthood

ow.ly/OEOt5101CjB

Keep up with the conversations that matter in medicine with Medthority. Explore independent medical education, expert insights, congress highlights, and clinical resources created to support your practice
ow.ly/nR495101est

📰 It’s News-day Tuesday! New research highlights the benefits of continuous glucose monitoring for people with type 2 diabetes who do not use insulin. Plus, scientists reveal that ovaries remain biologically active after menopause
ow.ly/mi605100Z5g

This #LiverAwarenessMonth, explore the latest updates in alpha-1 antitrypsin deficiency (AATD) diagnosis, management and care with Medthority. Access expert perspectives and educational resources to support your clinical practice

ow.ly/FoZF5100Tga

That wraps our #ESMO26 coverage! If you missed any updates, head over to Medthority to catch up on expert insights and the highlights you need to know in lung cancer #Oncology #OncTwitter #MedX #MedEd

ow.ly/qPJA5100Zio

#ESMO26
ASTRIDE provided US data supporting serplulimab in ES-SCLC, with outcomes consistent with the phase 3 ASTRUM-005 trial.
📊 2-year OS: 32.2% vs 17.6% 📊 Median PFS: 5.4 vs 4.9 months
No new safety signals identified.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX

#ESMO26
The US bridging study ASTRIDE reported numerically longer overall survival with serplulimab plus chemotherapy versus atezolizumab plus chemotherapy in ES-SCLC.
📊 Median OS: 12.4 vs 10.2 months
Presented by @drgandara
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX

#ESMO26
Updated DeLLphi-304 data also showed sustained long-term benefit with tarlatamab in previously treated #SCLC.
📊 2-year OS: 30% vs 15%
📊 Sustained disease control ≥52 weeks: 24% vs 4%
No new safety signals.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky

#ESMO26
Extended follow-up from the phase 3 DeLLphi-304 trial showed durable survival benefit with tarlatamab in previously treated #SCLC.
📊 Median OS: 13.6 vs 8.4 months
📊 38% lower risk of death
Presented by @charlesrudin
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX

Next up, look out for our roundup of the key topics being discussed in the oral abstract session “Proffered paper session on non-metastatic NSCLC and other thoracic malignancies”, coming soon 👀

#ESMO26
Phase 1 data for SKB500, a B7-H3-targeted ADC, also demonstrated encouraging activity in heavily pretreated ES-SCLC.
📊 ORR: 62.5%-66.7%
📊 Median PFS: 5.6-8.1 months
Presented by Haifeng Liu.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky

#ESMO26
New data for ABBV-706, a first-in-class SEZ6-targeted ADC, showed promising activity in relapsed/refractory #SCLC.
📊 ORR: 56% at the recommended phase 3 dose
📊 Median OS: 12.4 months
Presented by @Annechiangmd
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky

What’s new in non-metastatic #SCLC at #ESMO26?
Get live updates and key takeaways on emerging ADCs from @Annechiangmd and Haifeng Liu #OncTwitter #MedEd #MedX #LungCancer #Oncology